Olema Pharmaceuticals inc Ordinary Shares OLMA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OLMA is a good fit for your portfolio.
News
-
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
-
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Olema Oncology to Participate in Upcoming Investor Conferences
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $9.83
- Day Range
- $9.51–10.09
- 52-Week Range
- $4.26–17.79
- Bid/Ask
- $9.93 / $9.96
- Market Cap
- $556.35 Mil
- Volume/Avg
- 434,481 / 838,218
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 70
- Website
- https://www.olema.com
Comparables
Valuation
|
Metric
|
OLMA
|
VOR
|
BMEA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.13 | 0.76 | 2.28 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OLMA
|
VOR
|
BMEA
|
|---|---|---|---|
Quick Ratio | 12.14 | 8.81 | 7.74 |
Current Ratio | 12.33 | 9.04 | 7.84 |
Interest Coverage | — | — | — |
Quick Ratio
OLMA
VOR
BMEA
Profitability
|
Metric
|
OLMA
|
VOR
|
BMEA
|
|---|---|---|---|
Return on Assets (Normalized) | −34.21% | −41.83% | −56.31% |
Return on Equity (Normalized) | −37.29% | −51.69% | −65.70% |
Return on Invested Capital (Normalized) | −40.75% | −47.03% | −67.02% |
Return on Assets
OLMA
VOR
BMEA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rdmxvvfgvc | Twfct | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xbvmvmx | Nykmh | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Spjwnnyp | Shwscml | $97.8 Bil | |
MRNA
| Moderna Inc | Bzrlztv | Dryj | $41.3 Bil | |
ARGX
| argenx SE ADR | Kqsjhnr | Cxvx | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Vdynlnjj | Xkp | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qxjszyqv | Gtfjdsx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Svdjhcp | Qydbvtv | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tmsgbybnx | Frkbfmc | $12.5 Bil | |
INCY
| Incyte Corp | Hrkcjtcqv | Wmtpt | $11.6 Bil |